New Delhi, Nov 6 (IANS) While early detection of Alzheimer’s disease is crucial for better outcomes, a report on Wednesday said that blood-based tests are emerging as valuable tools.
The report by GlobalData, a data and analytics company, offers accessible alternatives to PET scans and cerebrospinal fluid (CSF) analysis.
Currently, Alzheimer’s affects over 55 million people globally, and cases are projected to triple by 2050.
Advances in diagnostic methods that can make diagnosis faster, less invasive, and more affordable can help in the timely intervention of the neurodegenerative disease. However, the report said questions remain about their real-world impact on patient outcomes.
Ashley Clarke, Senior Medical Analyst at GlobalData said that blood-based biomarker tests that are cost-effective and efficient in early assessment, have taken a major leap forward in diagnostics with it being used for conditions like heart attacks.
“For Alzheimer’s disease, reliable and accessible testing could lead to earlier detection, giving patients more time to pursue interventions and lifestyle changes,” Clarke said.
According to GlobalData’s Pipeline Products Database, more than 150 in vitro diagnostic tests for Alzheimer’s disease are currently in development. However, the USFDA has yet to grant full approval to blood-based Alzheimer’s tests.
“With high negative predictive values, blood-based tests could serve as reliable screening tools, helping reserve hospital resources for procedures such as PET scans for patients most likely to need them,” Clarke said.
GlobalData reports that at least five pipeline devices are now in the regulatory approval process across the US and Europe, yet ethical and regulatory challenges persist.
These tests raise concerns about overdiagnosis, exposure of sensitive health data, and the potential for insurers to adjust premiums based on test outcomes.
Predictive testing also introduces ethical considerations around informed consent, and potential psychological impacts for patients learning their risks in a disease still lacking a cure, the report said.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
